| Targeting ubiquitination machinery in cystic fibrosis: Where do we stand? T Okiyoneda, C Borgo, V Bosello Travain, N Pedemonte, M Salvi Cellular and Molecular Life Sciences 81 (1), 271, 2024 | | 2024 |
| P109 Safety of elexacaftor/tezacaftor/ivacaftor in patients 6 through 18 years with cystic fibrosis and at least one F508del allele: a retrospective Italian multicenter study V Terlizzi, C Fevola, S Presti, A Castaldo, V Daccò, L Claut, A Sepe, ... Journal of Cystic Fibrosis 23, S118-S119, 2024 | | 2024 |
| SUMOylation Inhibition Enhances Protein Transcription under CMV Promoter: A Lesson from a Study with the F508del-CFTR Mutant C Borgo, C D’Amore, V Capurro, V Tomati, N Pedemonte, ... International Journal of Molecular Sciences 25 (4), 2302, 2024 | | 2024 |
| Hyperbilirubinemia and Gilbert's syndrome in Cystic Fibrosis patients treated with elexacaftor/tezacaftor/ivacaftor V Terlizzi, S Timpano, M Salvi, A Tosco, A Castaldo, C Fevola, G Leonetti, ... Journal of cystic fibrosis: official journal of the European Cystic Fibrosis …, 2023 | 5 | 2023 |
| Exploring Protein Kinase CK2 Substrate Recognition and the Dynamic Response of Substrate Phosphorylation to Kinase Modulation L Cesaro, AM Zuliani, V Bosello Travain, M Salvi Kinases and Phosphatases 1 (4), 251-264, 2023 | 1 | 2023 |
| Kinases and Phosphatases: The Challenge of a New Journal Entirely Focused on Post-Translational Modifications M Salvi Kinases and Phosphatases 1 (1), 1-3, 2023 | | 2023 |
| Analysis of the phosphoproteome of CK2α(–/–)/Δα′ C2C12 myoblasts compared to the wild-type cells C Borgo, L Cesaro, T Hirota, K Kuwata, C D'Amore, T Ruppert, R Blatnik, ... Open Biology 13 (2), 220220, 2023 | 6 | 2023 |
| KDM2A and KDM3B as Potential Targets for the Rescue of F508del-CFTR C D’Amore, C Borgo, V Bosello Travain, M Salvi International Journal of Molecular Sciences 23 (17), 9612, 2022 | 4 | 2022 |
| Targeting the E1 ubiquitin-activating enzyme (UBA1) improves elexacaftor/tezacaftor/ivacaftor efficacy towards F508del and rare misfolded CFTR mutants C Borgo, C D’Amore, V Capurro, V Tomati, E Sondo, F Cresta, ... Cellular and Molecular Life Sciences 79 (4), 192, 2022 | 12 | 2022 |
| Kinases and Phosphatases: The Challenge of a New Journal Entirely Focused on Post-Translational Modifications. Kinases Phosphatases 2023, 1, 1–3 M Salvi | | 2022 |
| Development of small cyclic peptides targeting the CK2α/β interface EL Atkinson, J Iegre, C D’Amore, P Brear, M Salvi, M Hyvönen, DR Spring Chemical Communications 58 (30), 4791-4794, 2022 | 3 | 2022 |
| Grass pollen as a trigger for anaphylaxis: Case report of two patients DA Salpietro, S Rossi, M Salvi, S Zaffarano, L Ruggeri, R Badolato, ... ALLERGY 76, 293-293, 2021 | | 2021 |
| Targeting CK2 in cancer: a valuable strategy or a waste of time? M Salvi, C Borgo, LA Pinna, M Ruzzene Cell death discovery 7 (1), 325, 2021 | 31 | 2021 |
| A mutational approach to dissect the functional role of the putative CFTR “PTM-CODE” C D'Amore, C Borgo, M Salvi Journal of Cystic Fibrosis 20 (5), 891-894, 2021 | 3 | 2021 |
| How can a traffic light properly work if it is always green? The paradox of CK2 signaling C Borgo, C D’Amore, L Cesaro, S Sarno, LA Pinna, M Ruzzene, M Salvi Critical Reviews in Biochemistry and Molecular Biology 56 (4), 321-359, 2021 | 24 | 2021 |
| Protein kinase CK2: a potential therapeutic target for diverse human diseases C Borgo, C D’Amore, S Sarno, M Salvi, M Ruzzene Signal transduction and targeted therapy 6 (1), 183, 2021 | 197 | 2021 |
| Comparing the efficacy and selectivity of Ck2 inhibitors. A phosphoproteomics approach C Borgo, L Cesaro, T Hirota, K Kuwata, C D’Amore, T Ruppert, R Blatnik, ... European Journal of Medicinal Chemistry 214, 113217, 2021 | 15 | 2021 |
| Editorial of Special Issue “Protein Post-Translational Modifications in Signal Transduction and Diseases” C D’Amore, M Salvi International Journal of Molecular Sciences 22 (5), 2232, 2021 | 1 | 2021 |
| Contribution of the CK2 Catalytic Isoforms α and α’to the Glycolytic Phenotype of Tumor Cells F Zonta, C Borgo, CP Quezada Meza, I Masgras, A Rasola, M Salvi, ... Cells 10 (1), 181, 2021 | 10 | 2021 |
| Role of CK2 inhibitor CX-4945 in anti-cancer combination therapy–potential clinical relevance C D’Amore, C Borgo, S Sarno, M Salvi Cellular Oncology 43, 1003-1016, 2020 | 64 | 2020 |
Pinna LAUniversità di Padova, Dipartimento di Scienze Biomediche在 unipd.it 的电子邮件经过验证
